PS
Therapeutic Areas
Cardurion Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PDE9 Inhibitor | Heart Failure (HFrEF and HFpEF) | Clinical |
| CaMKII Inhibitor | Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Heart Failure, Atrial Fibrillation | Clinical |
Leadership Team at Cardurion Pharmaceuticals
ME
Michael E. Mendelsohn, M.D.
Founder and Chief Strategy Officer
HK
Howard K. Surks, M.D.
Chief Medical and Scientific Officer
ER
Elizabeth Radcliffe
Chief Financial Officer
CN
Charlotte Newman
Chief Business & Operations Officer